Microfluidic technology is rapidly emerging as a game-changing tool in breast cancer research — offering more realistic biological modeling and powerful new avenues for detection, treatment, and understanding of tumor progression. Traditional cell cultures and animal models often fail to replicate the complexity of human tissue environments, limiting insights into cancer behavior and therapy responses. Microfluidic systems overcome these challenges by enabling 3D cellular co-cultures and organ-on-a-chip platforms that closely mimic in vivo conditions
Key highlights from the review include:
🔹 Realistic Tumor Models: Microfluidic devices recreate tissue-level microenvironments to study breast cancer initiation, growth, and metastasis more accurately than conventional methods
🔹 Metastasis Investigation: These systems help simulate cancer cell invasion, intravasation, and extravasation, enabling deeper insights into how tumors spread to distant organs.
🔹 Detection & Dormancy Studies: Microfluidic platforms are expanding into early detection tools and models for cancer dormancy—a phase where cancer cells survive long after treatment before recurring.
🔹 Therapeutic Screening: Integrating drug testing within microfluidic chips accelerates evaluation of novel therapies and personalized medicine strategies.
🔹 Future Potential: As organ-on-a-chip systems evolve, their role in breast cancer research—from basic biology to clinical applications—is set to grow significantly.
Microfluidics is more than a research tool—it’s a bridge to better diagnostics and treatment outcomes in the fight against breast cancer.
